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Abstract 
Background 
Obstructive sleep apnea (OSA) is a health hazard since it is associated with neurocognitive 
dysfunction and cardio-metabolic diseases.  The prevalence of OSA among people with 
serious mental illness (SMI) is unclear.   
Method 
We searched major electronic databases from inception till 06/2015.  Articles were included 
that reported the prevalence of OSA determined by polysomnography (PSG) or an apnea-
hypopnea index (AHI) >5 events/hr, in people with major depressive disorder (MDD), 
bipolar disorder (BD) or schizophrenia.  A random effects meta-analysis calculating the 
pooled prevalence of OSA and meta-regression of potential moderators were performed.   
Results 
Twelve articles were included representing 570,121 participants with SMI (mean age=38.3 
years (SD=7.5)), 45.8% male (range=32-80.4) and mean body mass index (BMI) 25.9 
(SD=3.7).  The prevalence of OSA in SMI in clinical studies was 25.7% (95% CI 13.9 to 
42.4%, n=1,535). Higher frequencies of OSA were seen in MDD (36.3%, 19.4 - 57.4%, 
n=525) than in BD (24.5%, 95% CI 10.6 - 47.1, n=681) and schizophrenia (15.4%, 95% CI 
5.3 - 37.1%, n=329).  The prevalence of OSA in 568,586 people with SMI from population 
cohort studies was 10.7% (95% CI 2.4 - 37.0%) and 19.8% (95% CI 2.5 - 70.0%) in 358,853 
people with MDD.  Increasing age (β=0.063, 95% CI 0.0005 -0.126, p=0.04, N=10) and BMI 
predicted increased prevalence of OSA (β=0.1642, 95% CI 0.004 - 0.3701, p=0.04, N=9).   
Conclusion 
People with SMI (particularly MDD) have a high prevalence of OSA.  Screening for and 
interventions to manage OSA in SMI including those focused on reducing BMI are 
warranted.  
Key words: obstructive sleep apnea, sleep, serious mental illness, major depressive disorder, 
bipolar disorder, schizophrenia  
  
Introduction 
Obstructive sleep apnea (OSA) is an important cause for a number of medical comorbidities 
and premature mortality (Punjabi, 2008).  OSA is characterised by recurrent episodes of 
pharyngeal obstructions during sleep resulting in a reduction in airflow which can cause 
derangements in gaseous exchange and disturbed sleep (Punjabi, 2008; Sharafkhaneh, Giray, 
Richardson, Young, & Hirshkowitz, 2005; Sharafkhaneh, Richardson, & Hirshkowitz, 2004).  
As a result OSA is associated with a range of adverse outcomes including daytime sleepiness 
(Johns, 1993) and cognitive dysfunction (Olaithe & Bucks, 2013). It may result in the 
development of hypertension (Peppard, Young, Palta, Dempsey, & Skatrud, 2000), 
cardiovascular disease (Peker, Carlson, & Hedner, 2006) and abnormalities in glucose 
metabolism (Punjabi & Polotsky, 2005).  Moreover, OSA often has a deleterious impact on 
quality of life (Punjabi, 2008) and is associated with symptoms of anxiety and depression 
(Rezaeitalab, Moharrari, Saberi, Asadpour, & Rezaeetalab, 2014).   
People with serious mental illness (SMI) (defined as major depressive disorder (MDD), 
bipolar disorder (BD) and schizophrenia spectrum disorders) have significantly poorer 
physical health than the general population and are at increased risk of comorbidities (Smith, 
Langan, McLean, Guthrie, & Mercer, 2013a; Smith et al., 2013b; Stubbs et al., 2014).  Of 
particular concern is the high prevalence of obesity (Mitchell, Vancampfort, De Herdt, Yu, & 
De Hert, 2013a; Mitchell et al., 2013b) diabetes (Stubbs , Vancampfort, De Hert, & Alex, 
2015 (in press); Vancampfort, Mitchell, De Hert, & Stubbs, 2015 (in press)) and metabolic 
syndrome (Mitchell et al., 2013a; Mitchell et al., 2013b).  
More recently, research has considered the relationship between SMI and respiratory 
diseases.  For instance, in a population cohort study (Partti et al., 2015) demonstrated that 
schizophrenia is associated with increased odds of having chronic obstructive pulmonary 
disease (COPD, OR=4.2) and chronic bronchitis (OR=3.8). Furthermore, reduced lung 
function (Vancampfort et al., 2014) can negatively influence participation in daily life among 
patients with schizophrenia.  One of the most prevalent respiratory disorder is OSA.  Key risk 
factors for OSA include obesity, craniofacial abnormalities (Sutherland, Lee, & Cistulli, 
2012), allergic rhinitis (Farabollini, Braschi, & Bonifazi, 2009) and cardiovascular disease 
(Young, Skatrud, & Peppard, 2004).  In addition, lifestyle factors such as smoking and 
alcohol misuse increase an individual’s risk of OSA (Punjabi, 2008). These comorbidities and 
lifestyle factors are particularly prevalent among people with SMI and therefore it is 
reasonable to assume that this group may be at increased risk of OSA. As such, the 
identification and management of OSA in people with SMI may be important in preventing 
or attenuating cardio-metabolic comorbidities associated with SMI (Punjabi, 2008; Young et 
al., 2004).  The relationship between OSA and cardiovascular disease, stroke, hypertension 
and altered glucose metabolism is complex and appears  to  be  b id i rec t ional  (Punjabi, 
2008; Young et al., 2004).  Nevertheless, understanding the prevalence of OSA in people 
with SMI is important.   
Previously, a number of narrative systematic reviews have considered the prevalence of OSA 
in schizophrenia (Kalucy, Grunstein, Lambert, & Glozier, 2013), and SMI more generally 
(Gupta & Simpson, 2015).  Whilst not focussing on OSA, another review (Plante & 
Winkelman, 2008) established the critical relationship between sleep disturbances generally 
and bipolar disorder.  Although these reviews have advanced the field, a number of 
limitations persist.  First, none have attempted to conduct a meta-analysis and the prevalence 
of OSA was limited to considering individual studies as single entities or calculating 
arithmetic means or medians of the prevalence of OSA.  Meta-analyses enable the pooling of 
data across studies in order to provide a more accurate effect size than when individual 
studies are considered separately (Ioannidis, 2009).  The recent reviews have also considered 
differing inclusion criteria when reviewing the literature on OSA.  For instance, (Gupta & 
Simpson, 2015) only considered studies measuring OSA confirmed by polysomnography 
(PSG) the gold standard recognised by the International Classification of Sleep Disorders 2nd 
edition (ICSD-2) (Medicine, 2005) criteria.  However, (Kalucy et al., 2013) considered ‘sleep 
disordered breathing’ including studies that report OSA from screening questionnaires.  
We aimed to conduct a meta-analysis investigating the prevalence of OSA in SMI and 
investigate diagnostic subgroup differences among people with MDD, BD and schizophrenia 
when determined according to standardised OSA measures.  Where possible, we anticipated 
conducting a comparative meta-analysis comparing the risk of OSA in people with SMI 
versus the general population.  Moreover, we sought to investigate differences reported in 
clinical and population cohort studies and conduct meta-regression analyses on potential 
moderator variables (if reported in at least 4 studies).    
Method 
This systematic review was conducted in accordance with the Meta-analysis of Observational 
Studies in Epidemiology guidelines (Stroup et al., 2000) and reported in accordance with the 
PRISMA statement (Moher, Liberati, Tetzlaff, & Altman, 2009) following a predetermined 
but unpublished protocol. 
 
Inclusion and exclusion criteria 
We included observational (clinical or population cohort) studies (prospective, retrospective 
or cross-sectional) that: (a) included people with a diagnosis of MDD, BD or schizophrenia 
spectrum disorders according to a structured clinical assessment and/ or meeting standardised 
diagnostic criteria (e.g. DSM-IV (Association, 2000) or ICD-10 (organisation, 1993)) (b) 
assessed for OSA in line with the international classification of sleep disorders, 2nd edition 
diagnostic and coding manual (Medicine, 2005).  This includes PSG (single or split-night) or 
OSA with apnea-hypopnea index (AHI, the number of episodes of apnea or hypopnea per 
hour during sleep) ≥ 5 events/h or the respiratory disturbance index (RDI) equivalent 
(Medicine, 2005).  We excluded studies that measured OSA with screening instruments alone 
or studies that identified those with SMI using a screening tool alone.  When we encountered 
studies reporting data from the same sample at different time points, we used the most recent 
data and/or the largest data set.  If necessary, we planned to contact study authors to confirm 
eligibility and/ or to acquire data, although this was not needed.   
 
Information sources and searches 
Two independent reviewers (B.S. and M.F.) searched Academic Search Premier, MEDLINE, 
Psychology and Behavioral Sciences Collection, PsycINFO, SPORTDiscus, CINAHL Plus 
and Pubmed from inception until June 2015. We used the key words ‘bipolar disorder’ or 
‘bipolar*’ or ‘affective disorders’ or ‘schizophrenia’ or ‘psychosis’ or ‘depression’ or major 
depression AND ‘sleep’ or ‘sleep apnea’ or ‘obstructive sleep apnea’.  In addition, the 
reference lists of all eligible articles and recent narrative systematic reviews on OSA and 
sleep disorders in people with SMI were reviewed (Gupta & Simpson, 2015; Kalucy et al., 
2013).  Only articles written in Italian or English were included.  
 
Study Selection 
After the removal of duplicates, two independent reviewers screened the titles and abstracts 
of all potentially eligible articles. Both authors applied the eligibility criteria, and a list of full 
text articles was developed through consensus. The two reviewers then considered the full 
texts of these articles and the final list of included articles was reached through consensus.   
 
Data Extraction 
Two authors (B.S. and M.F.) independently extracted data and recorded this in a 
predetermined database. The data collected from each article included: study design, 
geographical location, details of SMI participants (mean age, percentage of males, diagnosis 
method, body mass index (BMI), details of medications and chronicity of illness) and details 
regarding diagnosis.  In addition, we sought to extract data on the classification of OSA and 
number diagnosed with OSA.   
Methodological quality appraisal 
We used the Newcastle Ottawa Scale (NOS; (Wells, Shea., O'Connell, & Peterson)) to assess 
the methodological quality of all included articles.  We included studies without a control 
group due to the paucity of data  and such studies were treated as cross sectional case 
controlled studies for the purposes of methodological assessment. Naturally it was 
anticipated these studies to have a low methodological quality rating. The NOS assesses the 
quality of non-randomised trials and its validity and reliability has been established (Wells et 
al.) and such criterion is particularly essential when critically appraising studies without a 
control group.   The NOS focuses on three main methodological features: 1) the selection of 
the groups, 2) the comparability of the groups and 3) the ascertainment of the outcome of 
interest.  The maximum score that any study can achieve on the NOS is 9 points.  Studies 
that score 5 or more are normally considered of satisfactory methodological quality. Due to 
the paucity of literature we included studies with a score less than this (due to the absence 
of a control group). The methodological assessment was independently completed by two 
authors and consensus was reached through discussion.   
 
Meta- analysis 
We pooled individual study data using the DerSimonian-Laird proportion method 
(DerSimonian R. & N., 1988) which calculates pooled prevalence using inverse-variance 
weighted random effects meta-analysis with StatsDirect
®
 and Comprehensive Meta-
Analysis
®
 software (version 3). Due to anticipated heterogeneity, a random effects meta-
analysis was employed. If there were 3 or more studies with relevant data, we planned to 
calculate subgroup analyses of the prevalence of OSA according to SMI diagnostic 
classification.  We also anticipated completing separate subgroup analyses investigating the 
pooled prevalence of OSA in clinical and population cohort studies and conducted a 
comparative relative risk (RR) meta-analysis to establish if OSA is more common in people 
with SMI versus controls.  We assessed publication bias with the visual inspection of a funnel 
plot (Higgins JPT & S) and the Begg (Begg & Mazumdar, 1994) and Egger (Egger, Davey 
Smith, Schneider, & Minder, 1997) tests.  Finally, we conducted several meta-regression 
analyses (if N≥4) to investigate potential moderators (age, percentage males and BMI) with 
Comprehensive Meta-Analysis
®
 (version 3).  Despite a lack of consensus on the number of 
studies required for meta-regression, we chose to only conduct meta regression where data 
was available from 4 or more studies based on recent recommendations (Fu et al., 2011).  We 
anticipated conducting meta regression analyses to investigate the influence of mean age, 
methodological quality, percentage of males, psychopathology/ depressive symptoms, the 
percentage taking psychotropic and antipsychotic medication.  
Results 
Search results and study selection 
The initial search identified 2,215 publications. After removal of duplicates, 221 abstracts 
and titles were screened (Figure 1). At the full text review stage, 62 articles were considered 
and 50 articles were excluded with reasons which are listed in figure 1.  Thus, 12 articles met 
the eligibility criteria and were included in the review (Ancoli-Israel et al., 1999; Carney et 
al., 2006; Deldin, Phillips, & Thomas, 2006; Hattori, 2009; Hrubos-Strøm et al., 2012; Kelly, 
Douglas, Denmark, Brasuell, & Lieberman, 2013; Levine et al., 2001; Mysliwiec et al., 2013; 
Ong, Gress, San Pedro-Salcedo, & Manber, 2009; Sharafkhaneh et al., 2005; Soreca, 
Levenson, Lotz, Frank, & Kupfer, 2012; Winkelman, 2001). Details regarding the search 
results including reasons for exclusion of articles are summarised in figure 1.   
Figure 1 here 
Study and participant characteristics  
Across the 12 unique included studies 570,121 unique participants with SMI were included. 
One study included a substantial percentage of the participants included in our meta-analysis 
(about 99.7% of the whole sample). The mean age across the studies of participants was 38.3 
years (SD=7.5) and 45.8% of the included participants were male (range=32-80.4%).  The 
mean BMI across 10 studies with complete data was 25.9 (SD=3.7) (overweight).  Across the 
12 studies, 9 considered OSA in MDD (n=359,378)(Carney et al., 2006; Deldin et al., 2006; 
Hattori, 2009; Hrubos-Strøm et al., 2012; Levine et al., 2001; Mysliwiec et al., 2013; Ong et 
al., 2009; Sharafkhaneh et al., 2005; Winkelman, 2001).  Six studies provided data on 72,043 
people with BD (Hattori, 2009; Kelly et al., 2013; Levine et al., 2001; Sharafkhaneh et al., 
2005; Soreca et al., 2012; Winkelman, 2001) and 4 studies provided data on 138,700 people 
with schizophrenia spectrum disorders (Ancoli-Israel et al., 1999; Levine et al., 2001; 
Sharafkhaneh et al., 2005; Winkelman, 2001).  Only two of the included studies were 
population cohort designs (Hrubos-Strøm et al., 2012; Sharafkhaneh et al., 2005) and the 
remainder included clinical samples.  The average NOS was 4.25 (range 4-5).  Full details of 
the included studies according to SMI diagnosis are summarised in table 1.   
Table 1 here 
 
Meta-analysis of the prevalence of OSA in clinical studies  
Prevalence of OSA among people with SMI 
Data were pooled from 1,535 unique participants with SMI resulting in a pooled prevalence 
of OSA of 25.7% (95% CI 13.9 to 42.4, Q=156 (df=13) p<0.01) (figure 2).  The Begg (-0.9, 
p=0.59) and Egger tests (-0.45, p=0.79) did not demonstrate any evidence of publication bias 
in the overall pooled analyses. 
 
Prevalence of OSA among different diagnostic subgroups 
Data was pooled from 6 clinical studies from 522 people with MDD to establish a pooled 
prevalence of OSA of 36.3% (95% CI 19.4 to 57.4, Q=82.83, (df=6) p<0.01).  The pooled 
prevalence of OSA among 681 people with BD was 24.5% (95% CI 10.6 to 47.1, Q=26.55 
(df=4) p<0.01).  The prevalence of OSA among 329 people with schizophrenia was 15.4% 
(95% CI 5.3 to 37.1, Q=46 (df=3), p<0.01).  The prevalence of OSA in in each diagnostic 
subgroup is presented in figure 2. 
Figure 2 here 
Sensitivity analyses 
Two studies (Carney et al., 2006, Ong et al., 2009) focussing on people with MDD were 
identified as being potentially biased due to the nature of included participants.  Therefore, 
these were removed in a sensitivity analysis and the pooled prevalence of OSA among 378 
people with MDD was recalculated at 25.2% (95% CI 10.2 to 50.2, Q= 58, p<0.01).  The 
overall pooled prevalence of OSA in SMI established the pooled prevalence of OSA was 
25.5% (95% CI 16.6 to 37.6, Q=199, p<0.01, n=1,314).   
 
Meta regression of pooled prevalence of OSA in SMI 
Meta regression analysis using data from 10 studies established that a higher mean age 
predicted an increased prevalence of OSA in the SMI participants (β=0.063, 95% CI 0.0005 
to 0.126, z=1.97, p=0.04, R
2
=0.34).  Meta-regression with data from 9 studies established that 
higher BMI predicted increased prevalence of OSA (β=0.1642, 95% CI 0.004 to 0.3701, 
z=1.56, p=0.04, R
2
=0.23).  No relationship was found with the percentage of males in the 
studies (p>0.05, N=9) or methodological quality according to the NOS (p>0.05, N=10).   
 
Prevalence of OSA in population cohort studies 
Data were pooled from 4 samples utilising two studies including 359,378 people with MDD, 
72,043 with BD and 138,700 people with schizophrenia. As reported in Figure 3, the pooled 
prevalence of OSA among a total of 568,586 people with SMI was 10.7% (95% CI 2.4 to 
37.0, 1368.3 (df=3), p<0.01).  The pooled prevalence of OSA in MDD, calculated from 
pooled data from two unique studies was 19.8% (95% CI 2.5 to 70.0).   
Figure 3 here 
 
  
Discussion 
General findings 
Results our meta-analysis demonstrates in clinical studies that approximately a quarter of 
people with SMI meet the criteria for OSA. People with MDD appear to have a higher 
prevalence of OSA compared to people with BD or schizophrenia. However, after the 
removal of two potentially biased studies the prevalence of OSA in MDD appears similar to 
BD.  When we considered population cohort data only, the pooled prevalence of OSA was 
lower at 10.7%, although pooled data from the two MDD cohorts suggest that OSA is higher 
in this population (19.8%).  We found that both increasing age and increased BMI predict an 
elevated prevalence of OSA among people with SMI.   
 
The increased prevalence of OSA in MDD compared to other diagnostic subgroups is of 
interest and warrants further investigation. It has been previously suggested that sleep 
fragmentation associated with hypoxaemia and altered serotonergic neurotransmission, as 
well as common shared risk factors for both MDD and OSA may account for an increased 
prevalence of OSA in people with MDD (Schroder & O’Hara 2005). Among pathways 
linking OSA and MDD, low serotonin levels seem to play an important role since serotonin 
has been involved in both the development of depression (Muñoz, Mayoralas, Barbé, Pericás, 
& Agusti, 2000) and might also influence upper airway dilator motor neurons particularly 
through the hypoglossal nucleus (Canessa et al., 2011). In people with MDD, the early 
identification and treatment of OSA seems to correspond to a better improvement of 
depressive symptoms (Edwards et al., 2015). OSA and MDD are risk factors for the 
development of obesity (El-Ad & Lavie, 2005), cardiovascular disease (Vozoris, 2012), and 
metabolic syndrome (Lett et al., 2004), while there is also an increased risk in both disorders 
of excessive alcohol consumption (Harris, Glozier, Ratnavadivel, & Grunstein, 2009).  In 
addition, given that in the general population OSA is independently associated with 
metabolic syndrome (Coughlin, Mawdsley, Mugarza, Calverley, & Wilding, 2004), 
cardiovascular disease (Peker et al., 2006) and abnormalities in glucose metabolism (Punjabi, 
2008), the identification and management of OSA may prove also a valuable means to 
prevent cardiovascular disease in people with MDD.   
 
Obtaining the precise prevalence of OSA in the general population is challenging and many 
cases within the general population are under-recognised (Ravesloot, van Maanen, 
Hilgevoord, van Wagensveld, & de Vries, 2012), with previous research suggesting 1-2% and 
2-4% of women and men are affected (Gibson, 2005).  Others have suggested a higher 
prevalence in studies conducted in clinical settings with (Young et al., 1993) establishing a 
prevalence of 24% and 9% in males and females with an AHI>5.  Unfortunately, there were 
insufficient data to enable a comparative meta-analysis to directly compare the prevalence of 
OSA in people with SMI versus general population controls.  Thus, it remains unclear if 
people with SMI are at increased risk of OSA compared to people in the general population.  
However, the pooled prevalence of OSA in MDD was 36.3% which is higher than previous 
estimates in the general population (Young et al., 1993).  Studies that have previously 
investigated sleep disordered breathing in MDD defined according to structured clinical 
assessment have reported greatly increased rates of OSA, with odds ratios of over 5, thus also 
supporting our results that people with MDD are particularly at increased risk (Ohayon, 
2003).  Moreover, a previous narrative systematic review tabulated the median prevalence of 
OSA in MDD (Gupta & Simpson, 2015) and reported this as 48.1%.  Thus, utilising meta-
analysis we were able to establish that the prevalence of OSA in MDD in clinical settings 
appears to be less than that reported previously (Gupta & Simpson, 2015).  It was also 
possible to pool data from 358,853 people with MDD and establish the prevalence of OSA in 
population cohort studies is almost one in 5 (19.8%).  Given the likely bias attributed to the 
studies conducted in clinical settings, the prevalence in population studies may be a truer 
reflection of the actual prevalence of OSA.   
 
The pooled prevalence of OSA in BD in clinical settings was 24.5% and is comparable to 
clinical studies in the general population (Young et al., 1993), yet higher than the arithmetic 
median reported in a previous narrative review (19.8%) (Gupta & Simpson, 2015).  Our 
pooled analysis of 4 clinical studies in schizophrenia established that 15.4% are affected by 
OSA, lower than reported in the general population. A previous narrative review suggested 
people with schizophrenia have a particularly high prevalence of OSA (Kalucy et al., 2013). 
Our current findings should however be interpreted with caution given the limitations in the 
available data.  Moreover, only one representative study (Sharafkhaneh et al., 2005) adopted 
a population cohort study approach which reported 4.5% and 6.9% of people with 
schizophrenia and BD have OSA respectively.  Therefore, it is important that future 
representative research is conducted to attempt to build on the results of our review and 
establish the true prevalence of OSA in the diagnostic SMI groups.   
 
The finding that increasing BMI is a significant predictor of increased prevalence of OSA is 
of interest.  Many people with SMI experience increased levels of BMI and in particular 
central adiposity (De Hert et al., 2011; Gardner-Sood P, Lally J , & al, 2015) which is known 
to increase the risk of OSA in the general population (El-Ad & Lavie, 2005). Reasons for 
high BMI values in people with SMI could be the high prevalence of sedentary lifestyle 
(Stubbs et al., 2015) and the use of antipsychotic medications that could contribute to obesity 
in this population. Given this finding, there is further need to develop preventive lifestyle 
interventions to reduce weight gain in people with mental illness. Future work is needed to 
investigate the impact of medication on OSA risk in people with SMI.  Moreover, other 
sedative medications commonly prescribed to people with SMI such as benzodiazepines may 
also increase the risk of OSA (Gupta & Simpson, 2015). Research in the general population 
has established that men are at particularly increased risk of OSA (Gibson, 2005; Young et 
al., 1993). However, we were unable to elucidate any gender effects in our meta-regression 
analyses.  
 
There are a number of reasons why identifying and managing OSA is clinically important 
among people with SMI.  First, OSA can result in neurocognitive and mood deterioration 
among people with mental health problems through intermittent hypoxia and disrupted sleep 
(Bucks, Olaithe, & Eastwood, 2013; Gupta & Simpson, 2015). Clearly, this is an unwanted 
potential consequence among people who already experience compromised cognition and 
mood instability (Gupta & Simpson, 2015). Second, if left untreated there are considerable 
concerns that OSA may increase the risk of cardiovascular disease, impair glucose regulation 
and increase the risk of metabolic syndrome. Previous work from our group has extensively 
documented that people with SMI are at risk of metabolic syndrome (Gardner-Sood P et al., 
2015 (in press); Mitchell et al., 2013a; Mitchell et al., 2013b; Vancampfort et al., 2013) and 
diabetes (Stubbs  et al., 2015 (in press); Vancampfort et al., 2015 (in press)).  Emerging 
evidence has demonstrated a number of mechanisms which underlie the relationship between 
OSA and metabolic dysregulation including sympathetic activation, oxidative stress and 
related inflammation (JC & SM, 2012). Given that cardiovascular disease is a major cause of 
premature mortality in people with SMI (Walker, McGee, & Druss, 2015), the increased 
prevalence of OSA is a concern. OSA has been identified as a cause of sudden death in the 
community (Gami et al., 2013) and among psychiatric patients (Manu, Kane, & Correll, 
2011).The magnitude of the risk is predicted by the presence and severity of nocturnal 
hypoxemia (Gami et al., 2013), an issue of particular concern in psychiatric patients who 
refuse continuous positive airway pressure (CPAP) or Bilevel Positive Airway Pressure 
treatment and/or are treated with benzodiazepines or other CNS-depressant psychotropic 
drugs (Seda, Tsai, & Lee-Chiong, 2014).  A previous Cochrane review (Giles et al., 2006) 
suggests that CPAP may be effective in managing OSA, however there are no rigorous trials 
investigating this in people with SMI (Kalucy et al., 2013).   
 
Limitations 
Although this meta-analysis provides novel findings, there are a number of limitations that 
must be considered, particularly in light of the data available from the included studies. 
First, there was some heterogeneity encountered within the study design and participants.  
We attempted to negate this by conducting sub-group analyses and meta-regressions.  
Second, the pooled analyses on clinical studies of OSA may not be representative of the 
wider SMI populations.  The meta-analyses results drawn from population cohort studies 
were sparse but may be a more accurate reflection of the prevalence of OSA.  However, 
these should be interpreted in light of the caveats mentioned above (i.e. clinical setting and 
overshadowing of co-morbid medical conditions in patients with SMI), indicating the 
frequencies reported may be underestimates. In this sense, one study (Sharafkhaneh et al., 
2005), which accounted for the overwhelming majority of participants in or meta-analysis 
reported a lower prevalence of OSA than the other studies included in our analyses. Third, 
there was inadequate comparative data of healthy controls to conduct a meta-analysis to 
understand if people with SMI are at increased risk of OSA. Representative research is 
required to understand this further.  Fourth, there was inadequate data on important 
moderators such as antipsychotic medication which may influence OSA.  Future research is 
clearly required to better understand these relationships.  Finally, our meta regression 
considered the SMI group as a whole since there was insufficient data to consider each 
diagnostic group separately.  However, this might have resulted in potentially spurious 
results, which should be clarified in larger representative studies within each diagnostic 
group.  Nevertheless, allowing for these caveats our meta-analysis provides the most 
systematic quantitative analysis of the prevalence and predictors of the OSA in people with 
SMI.   
 
Conclusion 
Our meta-analysis established that 25.7% of people with SMI have OSA. Higher frequencies 
were found in MDD (36.3%) compared to BD (24.5%) and schizophrenia (15.4%) although 
for BD and schizophrenia our findings are unclear due to the small number of the studies 
included for these conditions.  Clearly people with SMI are at risk of OSA and this may 
negatively impact a range of health outcomes and therefore warrants closer attention in 
clinical practice.  Moreover, future representative research is required to better understand the 
incidence and prevalence of OSA across all people with SMI with a view to developing 
effective interventions.   
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Table 1- Summary of included studies 
Author Location, 
setting 
Population Participant 
details 
OSA 
measurement 
NOS 
summar
y score 
Clinical samples  
Levine et al., 
2001 
US, 
retrospectiv
e study 
MDD (n=43),  
BD (n=66), 
Schizophrenia 
(n=140), 
Schizoaffectiv
e (n=91) 
 
MDD 41 years, 
65% male 
BD 42 years, 
59% male 
Schizophrenia 
41 years 
Consecutive 
psychiatric 
patients. 
80% overall 
sample taking 
antipsychotic 
medication. 
Diagnosed by 
overnight 
polysomnography 
and 
oxyhemoglobin 
desaturation 
4 
Winkelman 
et al., 2001 
US, 
retrospectiv
e study 
MDD 
(n=176) 
BD (n=92) 
Schizophrenia 
(n=46) 
MDD 
39.9±16.6 
years, 51.1% 
male, BMI 
27±8.6, 10.8% 
taking 
neuroleptics 
 
BD 38±15 
years, 32.6% 
male, BMI 
27.9 ± 7.6, 
21.7% taking 
psychotropic 
medicine 
 
Schizophrenia 
35.3 ± 8.4 
years, 80.4% 
male, BMI 
31.5 ± 8.2, 
100% taking 
psychotropic 
medication. 
 
All patients 
were referred 
to a sleep 
disorder 
Defined as 
present if the RDI 
exceeded 10 (or 
20) apnea + 
hypopnea per 
hour of sleep 
4 
consultation 
service from 
an inpatient 
psychiatric 
hospital 
Deldin et 
al., 2005 
US, cross 
sectional 
MDD (n=19) 34.47±11.52 
years, 21% 
male, BMI 
26.13±7.40, 
Antidepressant
s: 37% 
Sedative 
hypnotics: 
16% 
Recruited 
through 
newspaper 
advert and part 
of larger trial 
on MDD and 
memory.  
Polysomnography
, RDI > 5 major 
events 
per hour 
4 
Carney et 
al., 2006 
US, cross 
sectional 
MDD (n=53) 53.8±9 years, 
53% male, 
BMI 30.1±6.8 
Participants all 
had stable 
coronary heart 
disease.  
Polysomnography 
OSAHS 
(obstructive sleep 
apnea 
encompassing 
hypopnea 
syndrome) was a 
priori defined as 
≥5 apneic or 
hypopneic 
episodes per hour 
of sleep 
5 
Hattori M. 
et al., 2009 
Japan, 
cross 
sectional 
MDD (n=19) 
BD (n=13) 
Overall 75% 
sample were 
male, not 
possible to 
determine 
further 
participant 
details.  
Overnight PSG 
plus AHI ≥5, 
according to the 
International 
Classification of 
Sleep Disorders 
2nd edition 
(ICSD2); 
alternative 
criterion was 
AHI>10 for 
secondary 
analyses 
4 
Ong JC et 
al., 2009 
US, 
baseline 
RCT data 
MDD (n=51) 48.28±12.32 
years, 59% 
male,  
BMI 
Polysomnography
; a AHI score ≥15 
was considered 
diagnostic for 
4 
27.18±6.39 
All participants 
had comorbid 
insomnia 
 
OSA 
Mysliwiec et 
al., 2012 
US, 
retrospectiv
e 
MDD 
(n=164) 
Overall 93% 
sample male, 
not possible to 
determine 
further 
participant 
details.  
Cases were 
recruited 
among active 
duty military 
personnel 
PSG using the 
American 
Academy of 
Sleep Medicine 
alternative 
scoring method 
for hypopneas 
requiring a ≥50% 
decrease in the 
nasal pressure 
signal excursion 
from baseline 
lasting 10 sec or 
more with either a 
≥3% desaturation 
or an arousal. 
OSA cases were 
further 
distinguished in 
"mild" ones AHI 
5-15, or 
"moderate-to-
severe" OSAs if 
AHI score was 
>15. 
4 
Soreca I et 
al., 2014 
US, cross 
sectional 
BD (n=28) 41.7±9.8 years, 
32% male,  
BMI 33.8, all 
BD I 
Objective 
measurement of 
AHI>5 
4 
Kelly T. et 
al., 2013 
US, 
retrospectiv
e 
BD (n=482) 44.21+17 
years, 40% 
male, BMI 
26.7±5.51 
BD-I (n=58), 
BD-II (n=301) 
or BD-unclear 
(n=123) 
Clinical sleep lab 
for PSG, using 
the standard 
American 
Academy of 
Sleep Medicine 
criteria of an 
apnea index of at 
least 15 or at least 
5 with daytime 
hypersomnolence 
4 
Ancoli-
Israel et al., 
1999 
US, cross 
sectional 
Schizophrenia 
(n=52) 
59.6±8.9 years, 
67.30% male, 
BMI 28.5±7.4, 
84.60% taking 
antipsychotic 
The 
Medilog/Respitra
ce portable 
recording system 
was used in 
4 
medication conjunction with 
portable 
oxymetry to 
record sleep, 
RDI>10 
Population cohort studies  
Sharafkhane
h et al 2005 
US, 
retrospectiv
e cohort 
MDD (n= 
358,817) 
BD (n= 
71,362) 
Schizophrenia 
(n= 138,371) 
Overall 90.2% 
of sample were 
male.  No clear 
demographic 
data on 
diagnostic sub 
groups 
 
Inpatient 
records of 
Veteran’s 
Health 
Administration 
from 1992–
2001 
 
Confirmed 
medical diagnosis 
of OSA based on 
ICD criteria 
5 
Hrubos-
Strom H et 
al., 2012 
Norway, 
cross 
sectional 
MDD (n=36) 48.8±10.3 
years, 65.50% 
male, BMI 
29.1±5.2 
PSG and AHI> 5 
events h-1 were 
diagnosed with 
OSA following an 
initial screen with 
the Berlin sleep 
Screening 
questionnaire.   
5 
KEY: US=United States, MDD= Major depressive disorder, BD= bipolar disorder, RDI= 
respiratory disturbance index, PSG= polysomnography 
 
 
Highlights 
 Approximately one quarter of patients with serious mental illness had obstructive sleep 
apnea 
 The prevalence of OSA was higher in those with MDD (36%) as compared to BD (24%) and 
Schizophrenia (15%) 
 Similar to the general population, increasing age and BMI were predictors of OSA in patients 
with serious mental illness 
 
 
